Share Name Share Symbol Market Type Share ISIN Share Description
4D Pharma LSE:DDDD London Ordinary Share GB00BJL5BR07 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 749.50p 733.00p 749.50p 749.50p 749.50p 749.50p 55 16:35:17
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -10.1 -12.6 - 482.42

4D Pharma Share Discussion Threads

Showing 76 to 95 of 100 messages
Chat Pages: 4  3  2  1
27/09/2016 UKREG Holding(s) in Company They way I read that is that Aviva Investors Global Services has lent out 830k shares worth £6mn whilst also reducing their position by 1.5mn shares to <3%
Ignore Liquid Underpants. He is a rancid little recluse who sits all day in the middle of a field digitally pleasuring himself. (He never manages the end bit, though, LOL LOL). He fancies himself as a bit of an investment guru and gives advice on all kinds of shares none of which he knows anything about. For instance he's been slagging off Woodford's Patient Capital Trust for aeons, quite impotently. Indeed in July he was shorting it, or so he claimed. He was trying to get other holders to do the same. So what happened? They shot up about 15%, that's all! He is also pretty thick about other financial matters. He says he avoids making a profit at all costs in case he has to pay Capital Gains Tax! Can you believe it? As if!!! He also excuses himself for always making losses by saying that they can be very useful to put against his tax liabilities. The dope hasn't twigged that you've got to make said gains before the losses can be used. He has also been making psychopathic fantasy posts pretending to smash those that disagree with him with a cricket bat about the head! Weird ain't a strong enough word.....
Nice 10% rise today
I decided to buy back in to the stock today. Pharma stocks look like a solid play for the future and this looks to be an ideal takeover candidate or it will sell of some of its pipeline to a bug player who are actively looking for new products.
Hey, liquid kid, how's that short on WPCT that you were boasting about on July 4 getting on? I'll answer that: PATHETICALLY. What a Prat! What a totally failed investment guru! Mostly though, a complete loser.
Hey, liquid kid, how's that short on WPCT that you were boasting about on July 4 getting on? I'll answer that: PATHETICALLY. What a Prat! What a totally failed investment guru! Mostly though, a complete loser.
Woodford still keen on 4D's prospects... "Positive progress Since the period end, there has been some meaningfully positive and noteworthy news from several portfolio companies... 4D Pharma is at an earlier stage than Prothena but is establishing itself as a leading player in the emerging field of live biotherapeutics. It has announced very encouraging analysis on its phase I trial into a potential treatment for irritable bowel syndrome which will allow it to progress to the next stage of its clinical development."
Wood haf expected the same drop as US peer Seres Therapeutics Inc (NASDAQ:MCRB) 30.51 -3.99 (-11.57%) Irish drugmaker Shire Plc said it would buy the rights to an experimental bowel drug from Pfizer Inc to bolster its pipeline of gastrointestinal treatments. The drug, is designed to treat moderate-to-severe inflammatory bowel disease, has successfully completed mid-stage studies. IBD includes ulcerative colitis (UC) and Crohn's disease (CD)
Results for the year ended 31 December 2015 "A fair value assessment of the acquired assets and liabilities (of Tucana) has not yet been completed at the date of this financial information and so a full disclosure of the valuation of the acquired assets and liabilities has not been made." How can 4D Justify value of this investment? Well, it doesn't have to until next year end! Not that there were any assets anyway. Tucana Health Limited was set up on Wednesday the 6th of January 2016. to investigate microbiome signatures. 4D Pharma acquired Tucana on 10 Feb 16.
Recovering well. getting close to previous highs.
4D are creating live biotherapeutic (microbiome) treatments for major diseases... Clinical trials underway for IBS. Trials about to start for Crohn's Disease Identified an orally administered candidates that had shown efficacy in pre-clinical models of: Asthma, Allergic asthma, Rheumatoid arthritis, Multiple sclerosis, Breast cancer, Lung Cancer. ...More to come. Plus multi-million pound collaboration on microbiome treatment for Autism Plus Acquired start-up microbiome diagnostics company Tucana Health. i.e massive potential here. Microbiome modification is at the heart of revolutionary health science. 4D and OPTI are right at the heart of it.
Looks as though there is an offensive on at the moment hyping up this company. HTTP:// 'Tucana’s R&D is closely related to two of the company’s products: Blautix, a therapy for Irritable Bowel Syndrome (IBS) currently in Phase I clinical trials that seems to be having promising results, and MicroRx, a proprietary library of gut microbiota.' HTTP:// '4D pharma’s investment will be used to build further research capability in Tucana Health, and to hire key research staff.' - This was a paid in shares acquisition. No cash 'Longer term the company will focus on building a diagnostic platform across multiple disease areas mirroring the programmes developed by MicroRx' - So they are going to do the same thing in the hope of getting a different answer?
Creeping up again.
Must be more trial results coming soon.
The trial on the 'healthy individuals' well it, Didn't kill them. Didn't make them stronger either. In the Companys cunning simple plan One of the four D's is; Develop: Development is a significant expense so only do proof of concept milestone. So are they going to stop scratching around the IBS here and ask for more money? I'm all for enhancing 'good' bacteria but the company really looks like the pond scum of an investment. The most advanced product within the programme, ThetanixTM, comprises a naturally occurring bacteria found in the gut of healthy individuals. And WTF does 'brain-gut-microbiota axis' even mean? "Without the micro-biota, life could not exist, and we would have no knowledge of the Force. They continually speak to us, telling us the will of the Force. When you learn to quiet your mind, you'll hear them speaking to you." Qui-Gon Jinn, to Anakin SkyWoodford
Sounds positive - need to get more details though.
Confirmation RNS today that Invesco bought £21.7m worth in the placing.
Looks like Invesco and Woodford have stumped up all of today's £30m placing cash. And the IBS trial is expected to complete before the end of this year. A cynic might think the II's had been given a heads up of positive results!
RNS Number : 9779G 4d Pharma PLC 26 November 2015 4D pharma plc (the "Company" or "4D") Research Update on MicroRx Discovery Platform 4D pharma plc (AIM: DDDD), a pharmaceutical company focusing on the development of live biotherapeutics, today provides the following research update on MicroRx, its proprietary platform for the discovery of novel live biotherapeutics. Using MicroRx, 4D has to date focused on identifying innovative autoimmune, respiratory and CNS therapies. In the last 18 months the MicroRx platform has delivered a proprietary pipeline of 12 programmes and continues to be targeted at delivering more candidates across multiple disease areas. Over the last six months, the Company has focused part of this work in oncology and is pleased to report that it has identified an orally administered live biotherapeutic candidate that has shown efficacy in pre-clinical models of breast and lung cancers. Encouragingly, the efficacy demonstrated in these pre-clinical models is comparable to checkpoint inhibitors, a market the pharmaceutical industry expects to exceed $25bn in the next decade. As with its other development programmes, 4D will accelerate the cancer programme further towards the clinic, aiming to have it ready for testing in patients in 12 months. We will also be targeting the MicroRx platform towards other cancers. This is another significant step for 4D, broadening both the therapeutic base and addressable markets for the therapies developed by the MicroRx platform. Dave Norwood, Chairman, commented "We believe the work we have completed over the last six months may open the way for the development of a completely new class of cancer therapeutics. As we have demonstrated elsewhere in our pipeline, 4D is not only world leading in the discovery of novel live biotherapeutics, it also sets a new benchmark in the rapid development and clinical testing of new therapeutics. If, as we believe, we can demonstrate a favourable safety and efficacy profile, the work 4D has achieved could be a significant step forward in the treatment of cancer."
Chat Pages: 4  3  2  1
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:30 V: D:20161027 22:36:51